|
Array Shares Climb After Asthma Drug Shows Positive Phase 2 Results
Xconomy Array hopes ARRY-502 can become the next successful oral treatment for asthma, CEO Ron Squarer said during a conference call about the results. The market is substantial, and it has been 15 years since the FDA last approved an oral non-steroidal drug … |
View full post on asthma – Google News